New adjuvanted vaccines in pregnancy: What is known about their safety?

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1411-1422

  Herberts, Carla ^a   Melgert, Barbro ^b   Van Der Laan, Jan Willem ^a   Faas, Marijke ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

adjuvant; decidual immunology; immunology; pregnancy; safety; vaccination

Indexed keywords

AF 03; AFLUNOV; ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM SALT; ANGIOGENIC FACTOR; AREPANRIX; AS 03; AS 04; AVIAN INFLUENZA VACCINE; BACTERIAL VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GAMMA INTERFERON; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B VACCINE; HUMENZA; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 4; ISCOM; ISCOMATRIX; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PANENZA; RECOMBINANT HEPATITIS B VACCINE; SILGARD; SYNFLORIX; TETANUS TOXOID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BLASTOCYST; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DECIDUA; DENDRITIC CELL; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; EMULSION; FERTILIZATION IN VITRO; FETUS DEVELOPMENT; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLUENZA VACCINATION; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALAISE; MATERNAL WELFARE; MYALGIA; NATURAL KILLER CELL; NIDATION; NONHUMAN; ORGANOGENESIS; PLACENTA CIRCULATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPRODUCTION; REPRODUCTIVE TOXICITY; REVIEW; SYNCYTIOTROPHOBLAST; TERATOGENESIS; TERATOGENICITY; TH1 CELL; TH2 CELL; TOXICITY TESTING; TROPHOBLAST; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; VACCINATION; VACCINES;

EID: 78649501747     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.133     Document Type: Review

References (135)

1. Skowronski DM, De Serres G. Is routine infuenza immunization warranted in early pregnancy? Vaccine 27(35), 4754-4770 (2009).
2. Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Infuenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect. Dis. 8(1), 44-52 (2008).
3. Black SO, Shinefeld HR, France EK, Fireman BH, Platt ST, Shay D. Effectiveness of infuenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J. Perinatol. 21(6), 333-339 (2004).
4. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal infuenza immunization in mothers and infants. N. Engl. J. Med. 359(15), 1555-1564 (2008).
5. Ayoub DM, Yazbak FE. A closer look at infuenza vaccination during pregnancy. Lancet Infect. Dis. 8(11), 660-661 (2008).
6. Naleway AL, Smith WJ, Mullooly JP Delivering infuenza vaccine to pregnant women. Epidemiol. Rev. 28(1), 47-53 (2006).
7. Gall SA. Vaccines for pertussis and infuenza: recommendations for use in pregnancy. Clin. Obstet. Gynecol. 51(3), 486-497 (2008).
8. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect. Dis. 7(9), 614-624 (2007).
9. Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted infuenza vaccines during pregnancy-a retrospective analysis. Vaccine 28(7), 1877-1880 (2010).
10. Trundley A, Moffett A. Human uterine leukocytes and pregnancy. Tissue Antigens 63(1), 1-12 (2004).
11. Veenstra van Nieuwenhoven AL, Bouman A, Moes H et al. Endotoxin-induced cytokine production of monocytes of third-trimester pregnant women compared with women in the follicular phase of the menstrual cycle. Am. J. Obstet. Gynecol. 188(4), 1073-1077 (2003).
12. Lala PK, Chakraborty C. Factors regulating trophoblast migration and invasiveness: possible derangements contributing to preeclampsia and fetal injury. Placenta 24(6), 575-587 (2003).
13. Wells M. The pathology of gestational trophoblastic disease: recent advances. Pathology 39(1), 88-96 (2007).
14. Nagamatsu T, Schust DJ. The immunomodulatory roles of macrophages at the maternal-fetal interface. Reprod. Sci. 17(3), 209-218 (2010).
15. Lash GE, Robson SC, Bulmer JN. Review: functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta 31(Suppl.), S87-S92 (2010).
16. King A. Uterine leukocytes and decidualization. Hum. Reprod. Update 6(1), 28-36 (2000).
17. Williams PJ, Searle RF, Robson SC, Innes BA, Bulmer JN. Decidual leucocyte populations in early to late gestation normal human pregnancy. J. Reprod. Immunol. 82(1), 24-31 (2009).
18. Starkey PM, Sargent IL, Redman CWG. Cell populations in human early pregnancy decidua: characterization and isolation of large granular lymphocytes by fow cytometry. Immunology 65(1), 129-134 (1988).
19. Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D. Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum. Reprod. 6(6), 791-798 (1991).
20. Gustafsson C, Mjosberg J, Matussek A et al. Gene expression profling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS ONE 3(4), e2078 (2008).
21. Craven CM, Morgan T, Ward K. Decidual spiral artery remodelling begins before cellular interaction with cytotrophoblasts. Placenta 19(4), 241-252 (1998).
22. Hanna J, Goldman-Wohl D, Hamani Y et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12(9), 1065-1074 (2006).
23. + regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol. Reprod. 82(4), 698-705 (2010).
24. + regulatory T-cell subset. Immunology 112(1), 38-43 (2004).
25. bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J. Immunol. 180(8), 5737-5745 (2008).
26. + regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol. Hum. Reprod. 10(5), 347-353 (2004).
27. Heikkinen J, Mottonen M, Alanen A, Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin. Exp. Immunol. 136(2), 373-378 (2004).
28. Aluvihare VR, Betz AG. The role of regulatory T cells in alloantigen tolerance. Immunol. Rev. 212, 330-343 (2006).
29. Scholz C, Toth B, Brunnhuber R et al. Glycodelin a induces a tolerogenic phenotype in monocyte-derived dendritic cells in vitro. Am. J. Reprod. Immunol. 60(6), 501-512 (2008).
30. + dendritic cells in early human pregnancy decidua. Clin. Exp. Immunol. 151(3), 399-406 (2008).
31. + dendritic cells in the decidua of women with recurrent miscarriage and normal pregnancy. Placenta 25(2-3), 140-145 (2004).
32. + dendritic cells. Am. J. Pathol. 157(1), 159-169 (2000).
33. Gardner L, Moffett A. Dendritic cells in the human decidua. Biol. Reprod. 69(4), 1438-1446 (2003).
34. Miyazaki S, Tsuda H, Sakai M et al. Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. J. Leukoc. Biol. 74(4), 514-522 (2003).
35. Veenstra Van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of successful pregnancy. Hum. Reprod. Update 9(4), 347-357 (2003).
36. Redman CW, Sargent IL. Immunology of preeclampsia. Am. J. Reprod. Immunol. 63(6), 534-543 (2010).
37. Mestan K, Yu Y, Matoba N et al. Placental infammatory response is associated with poor neonatal growth: preterm birth cohort study. Pediatrics 125(4), e891-e898 (2010).
38. Sacks GP, Clover LM, Bainbridge DRJ, Redman CWG, Sargent IL. Flow cytometric measurement of intracellular Th1 and Th2 cytokine production by human villous and extravillous cytotrophoblast. Placenta 22(6), 550-559 (2001).
39. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl Acad. Sci. USA 93(2), 705-708 (1996).
40. Sargent IL. Maternal and fetal immune responses during pregnancy. Exp. Clin. Immunogenet. 10(2), 85-102 (1993).
41. Faas MM, Donker RB, van Pampus MG et al. Plasma of pregnant and preeclamptic women activates monocytes in vitro. Am. J. Obstet. Gynecol. 199(1), 84.e1-84.e8 (2008).
42. Mellembakken JR, Aukrust P, Olafsen MK, Ueland T, Hestdal K, Videm V. Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension 39(1), 155-160 (2002).
43. Davis D, Kaufmann R, Moticka EJ. Nonspecifc immunity in pregnancy: monocyte surface Fcg receptor expression and function. J. Reprod. Immunol. 40(2), 119-128 (1998).
44. Naccasha N, Gervasi MT, Chaiworapongsa T et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am. J. Obstet. Gynecol. 185(5), 1118-1123 (2001). (Pubitemid 33097374)
45. Luppi P, Haluszczak C, Betters D, Richard CAH, Trucco M, DeLoia JA. Monocytes are progressively activated in the circulation of pregnant women. J. Leukoc. Biol. 72(5), 874-884 (2002).
46. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce infammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet. Gynecol. 179(1), 80-86 (1998).
47. Luppi P, Haluszczak C, Trucco M, DeLoia JA. Normal pregnancy is associated with peripheral leukocyte activation. Am. J. Reprod. Immunol. 47(2), 72-81 (2002).
48. Ueda Y, Hagihara M, Okamoto A et al. Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. Hum. Immunol. 64(12), 1144-1151 (2003).
49. Darmochwal-Kolarz D, Rolinski J, Tabarkiewicz J et al. Blood myeloid and lymphoid dendritic cells are stable during the menstrual cycle but defcient during mid-gestation. J. Reprod. Immunol. 59(2), 193-203 (2003).
50. Shin S, Jang JY, Roh EY et al. Differences in circulating dendritic cell subtypes in pregnant women, cord blood and healthy adult women. J. Korean Med. Sci. 24(5), 853-859 (2009).
51. Miwa N, Hayakawa S, Miyazaki S et al. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-g increase in normal pregnancy but decrease in spontaneous abortion. Mol. Hum. Reprod. 11(12), 865-870 (2005).
52. von Rango U, Krusche CA, Beier HM, Classen-Linke I. Indoleamine- dioxygenase is expressed in human decidua at the time maternal tolerance is established. J. Reprod. Immunol. 74(1-2), 34-45 (2007).
53. Watanabe M, Iwatani Y, Kaneda T et al. Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy. Am. J. Reprod. Immunol. 37(5), 368-377 (1997).
54. Kuhnert M, Strohmeier R, Stegmuller M, Halberstadt E. Changes in lymphocyte subsets during normal pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 76(2), 147-151 (1998).
55. Borzychowski AM, Croy BA, Chan WL, Redman CWG, Sargent IL. Changes in systemic type 1 and type 2 immunity in normal pregnancy and preeclampsia may be mediated by natural killer cells. Eur. J. Immunol. 35(10), 3054-3063 (2005).
56. Beer AE, Kwak JY, Ruiz JE. Immunophenotypic profles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles. Am. J. Reprod. Immunol. 35(4), 376-382 (1996).
57. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol. Today 14(7), 353-356 (1993).
58. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin. Exp. Immunol. 117(3), 550-555 (1999).
59. Chaouat G, Menu E, Kinsky R, Brezin C. Immunologically mediated abortions: one or several pathways? Res. Immunol. 141(2), 188-195 (1990).
60. Haimovici F, Hill JA, Anderson DJ. The effects of soluble products of activated lymphocytes and macrophages on blastocyst implantation events in vitro. Biol. Reprod. 44(1), 69-75 (1991).
61. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am. J. Reprod. Immunol. 63(6), 601-610 (2010).
62. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5(3), 266-271 (2004).
63. + regulatory T cells are increased in the human early pregnancy decidua and have immunosuppressive activity. Am. J. Reprod. Immunol. 49, 356 (2003).
64. Ashkar AA, Di Santo JP, Croy BA. Interferon g contributes to initiation of uterine vascular modifcation, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J. Exp. Med. 192(2), 259-270 (2000).
65. Ashkar AA, Black GP, Wei Q et al. Assessment of requirements for IL-15 and IFN regulatory factors in uterine NK cell differentiation and function during pregnancy J. Immunol. 171(6), 2937-2944 (2003).
66. Hering L, Herse F, Verlohren S et al. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension 51(2), 554-559 (2008).
67. Zhang JH, He H, Borzychowski AM, Takeda K, Akira S, Croy BA. Analysis of cytokine regulators inducing interferon production by mouse uterine natural killer cells. Biol. Reprod. 69(2), 404-411 (2003).
68. Monk JM, Leonard S, McBey BA, Croy BA. Induction of murine spiral artery modifcation by recombinant human interferon-g. Placenta 26(10), 835-838 (2005
69. Weinberg ED. Pregnancy-associated depression of cell-mediated immunity. Rev. Infect. Dis. 6(6), 814-831 (1984).
70. Fink CG, Read SJ, Hopkin J, Peto T, Gould S, Kurtz JB. Acute herpes hepatitis in pregnancy. J. Clin. Pathol. 46(10), 968-971 (1993).
71. Lagerberg RE. Malaria in Pregnancy: a literature review. J. Midwifery Womens Health 53(3), 209-215 (2008).
72. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand. J. Rheumatol. 12(2), 69-72 (1983
73. Varner MW Autoimmune disorders and pregnancy. Semin. Perinatol. 15(3), 238-250 (1991).
74. Apitz K. A study on the generalized Shwartzman phenomenon. J. Immunol 29(3), 255-266 (1935).
75. Theiss W, Beller FK. Exchange transfusion experiments in rats inducing intravascular coagulation. Surg. Gynecol. Obstet. 135(5), 713-716 (1972).
76. Bakker WW, Poelstra K, Timmerman W, Hardonk MJ, Koiter TR, Schuiling GA. Experimental endotoxemia in pregnancy: in situ glomerular microthrombus formation associated with impaired glomerular adenosine diphosphatase activity J. Lab. Clin. Med. 114(5), 531-537 (1989).
77. Bakker WW, Timmerman W, Poelstra K, Schuiling GA. Endotoxin induced intraplacental thrombotic tendency and decreased vascular ADPase in the pregnant rat. Placenta 13(3), 281-290 (1992).
78. Visscher CA, Faas MM, Bakker WW, Schuiling GA. Reproductive condition, glomerular adenosine diphosphatase activity, and platelet aggregation in the rat: effect of endotoxin. Biol. Reprod. 49(6), 1303-1309 (1993).
79. Faas MM, Schuiling GA, Baller JFW, Visscher CA, Bakker WW. A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am. J. Obstet. Gynecol. 171(1), 158-164 (1994).
80. Faas MM, Schuiling GA, Baller JFW, Bakker WW. Glomerular infammation in pregnant rats after infusion of low dose endotoxin: an immunohistological study in experimental preeclampsia. Am. J. Pathol. 147(5), 1510-1518 (1995).
81. + T cells. J. Leukoc. Biol. 78(6), 1273-1280 (2005).
82. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 65(20), 3231-3240 (2008).
83. Faas MM, van der Schaaf G, Borghuis T et al. Extracellular ATP induces albuminuria in pregnant rats. Nephrol. Dial. Transplant. 25(8), 2468-2478 (2010).
84. Arad M, Atzil S, Shakhar K, Adoni A, Ben-Eliyahu S. Poly I-C induces early embryo loss in F344 rats: a potential role for NK cells. Am. J. Reprod. Immunol 54(1), 49-53 (2005).
85. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-a-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am. J. Hypertens. 15(2 Pt 1), 170-175 (2002).
86. Athanassakis I, Aifantis Y, Ranella A, Vassiliadis S. Production of embryotoxic IgG antibodies during IFN-g treatment of pregnant mice. Am. J. Reprod. Immunol 36(2), 111-117 (1996).
87. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 14(11-12), 541-551 (2009).
88. Garcon N, Chomez P, Van MM. Glaxo Smith Kline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007).
89. Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet 101, 227-234 (1925).
90. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes: XVII-XXIV J. Pathol. Bacteriol. 29, 31-40 (1926).
91. Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines 6(4), 559-578 (2007).
92. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009).
93. De Gregorio E, D'Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 21(3), 339-345 (2009).
94. Mills KH. Designer adjuvants for enhancing the effcacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunol. Lett. 122(2), 108-111 (2009).
95. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1), 18-27 (1998).
96. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21(1), 23-29 (2009).
97. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741-747 (2009).
98. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc. Natl Acad. Sci. USA 95(2), 588-593 (1998).
99. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997).
100. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180(8), 5402-5412 (2008).
101. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 27(33), 4388-4401 (2009).
102. Dupuis M, Denis-Mize K, LaBarbara A et al. Immunization with the adjuvant MF59 induces macrophage traffcking and apoptosis. Eur. J. Immunol. 31(10), 2910-2918 (2001).
103. Klinman D. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25(3-4), 135-154 (2006).
104. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6(5), 761-772 (2007).
105. + T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
106. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
107. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for fu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82(6), 740-744 (2007).
108. Singh M, Carlson JR, Briones M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16(19), 1822-1827 (1998).
109. Baudner BC, Ronconi V, Casini D et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26(6), 1477-1485 (2009).
110. Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of infuenza vaccination during pregnancy. Am. J. Obstet. Gynecol. 201(6), 547-552 (2009).
111. Munoz FM, Greisinger AJ, Wehmanen OA et al. Safety of infuenza vaccination during pregnancy. Am. J. Obstet. Gynecol. 192(4), 1098-1106 (2005).
112. Silveira CM, Caceres VM, Dutra MG, Lopes-Camelo J, Castilla EE. Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Bull. World Health Organ. 73(5), 605-608 (1995).
113. Ryan MA, Seward JF. Pregnancy, birth, and infant health outcomes from the National Smallpox Vaccine in Pregnancy Registry, 2003-2006. Clin. Infect. Dis. 46(Suppl. 3), S221-S226 (2008).
114. Ornoy A, Arnon J, Feingold M, Ben Ishai P. Spontaneous abortions following oral poliovirus vaccination in frst trimester. Lancet 335(8692), 800 (1990).
115. Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA. Early exposure to yellow fever vaccine during pregnancy. Trop. Med. Int. Health 12(7), 833-837 (2007).
116. Ryan MA, Smith TC, Sevick CJ et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am. J. Epidemiol. 168(4), 434-442 (2008).
117. Veenstra Van Nieuwenhoven AL, Bouman A, Moes H et al. Cytokine production in natural killer cells and lymphocytes in pregnant women compared with women in the follicular phase of the ovarian cycle. Fertil. Steril. 77(5), 1032-1037 (2002).
118. Puig-Barbera J, Diez-Domingo J, Varea AB et al. Effectiveness of MF59-adjuvanted subunit infuenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25(42), 7313-7321 (2007).
119. Dana A, Buchanan KM, Goss MA et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet. Gynecol. 114(6), 1170-1178 (2009).
120. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007). (Pubitemid 46740303)
121. Smith-McCune K, Sawaya GF. Update on quadrivalent human papillomavirus vaccination and pregnancy outcomes: is contraception advisable? Obstet. Gynecol. 114(6), 1168-1169 (2009).
122. Pentsuk N, Van Der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B Dev. Reprod. Toxicol. 86(4), 1-17 (2009).
123. Simister NE. Placental transport of immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
124. Dorosko SM, Ayres SL, Connor RI. Induction of HIV-1 MPR649-684-specifc IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine. Vaccine 26(42), 5416-5422 (2008).
125. de la Fe C, Assuncao P, Saavedra P, Tola S, Poveda C, Poveda JB. Field trial of two dual vaccines against Mycoplasma agalactiae and Mycoplasma mycoides subsp. mycoides (large colony type) in goats. Vaccine 25(12), 2340-2345 (2007).
126. Ito SI, Ishii KJ, Shirota H, Klinman DM. CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect. Immun. 72(6), 3543-3548 (2004).
127. Heldens JGM, Pouwels HGW, Derks CGG, Van de Zande SMA, Hoeijmakers MJH. The frst safe inactivated equine infuenza vaccine formulation adjuvanted with ISCOM-matrix that closes the immunity gap. Vaccine 27(40), 5530-5537 (2009).
128. Menzies FM, Henriquez FL, Roberts CW. Immunological control of congenital toxoplasmosis in the murine model. Immunol. Lett. 115(2), 83-89 (2008).
129. Scott JR, Feldbush TL, Covault JM. A study of maternal lymphoid organs and the progeny following treatment with immunomodulating agents during pregnancy. Clin. Exp. Immunol. 30(3), 393-402 (1977).
130. Baylis F. Pregnant women deserve better. Nature 465(7299), 689-690 (2010).
131. Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2) e4384 (2009).
132. Luheshi GN. Cytokines and fever. Mechanisms and sites of action. Ann. NY Acad. Sci. 856, 83-89 (1998).
133. Aaltonen R, Heikkinen T, Hakala K, Laine K, Alanen A. Transfer of proinfammatory cytokines across term placenta. Obstet. Gynecol. 106(4), 802-807 (2005).
134. Winkler M, Rath W. [The role of cytokines in the induction of labor, cervical ripening and rupture of the fetal membranes]. Z. Geburtsh. Neonatol 200(Suppl. 1), 1-12 (1996).
135. Hendrickx AG, Makori N, Peterson P. Nonhuman primates: their role in assessing developmental effects of immunomodulatory agents. Hum. Exp. Toxicol. 19(4), 219-225 (2000).